HOBOKEN, N.J. (June 3, 2013) - The Hemophilia Association of New Jersey (HANJ) honored Octapharma USA President Flemming Nielsen as its Humanitarian Man of the Year during its annual fundraising dinner. Nielsen also is a member of the Management Board of Octapharma AG, the world's largest independent human protein products manufacturer, and the parent company of Octapharma USA.
"It is great honor to be selected for this award," said Nielsen. "Our partnerships with patient organizations like HANJ are very important to Octapharma USA because we are committed to providing patients with life enhancing and saving therapies that will improve quality of life. Patient safety is always our first priority so this is indeed a very special honor."
Nielsen joined Octapharma AG in September 2003 at its headquarters in Lachen, Switzerland, holding several financial management positions. He transferred to the U.S. in 2004 when Octapharma entered the American marketplace. Born and raised in Denmark, he earned a B.A. in Business from the Copenhagen Business School.
Despite significant competition in the U.S., Octapharma has grown marketshare every year and Nielsen points to community partnership as the main reason.
"The U.S. is a key market in Octapharma's strategic growth plans," according to Nielsen. "The U.S. is vital to our future as a company and our product portfolio is growing. Octapharma's success is mainly due to the strong collaborative relationships we have established with U.S. patient and professional organizations and we look forward to strengthening that bond in the future."
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma AG is the world's largest independent human protein products manufacturer and has been committed to patient care and medical innovation for 30 years. With a broad and expanding pipeline, Octapharma's core business is the development, production, and sale of high quality human protein therapies from both human plasma and human cell-lines, including intravenous immunoglobulin and von Willebrand Factor/Coagulation Factor VIII. Octapharma employs 5,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, New Jersey. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharma.com, www.octaplasus.com, or www.wilateusa.com.